Stifel analyst, Thomas Shrader, reiterated his Buy rating on shares of Voyager Therapeutics (NASDAQ: VYGR) after the company announced Sanofi-Genzyme’s ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE